Coya Therapeutics, Inc.
General ticker "COYA" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $94.0M (TTM average)
Coya Therapeutics, Inc. does not follow the US Stock Market performance with the rate: -13.5%.
Estimated limits based on current volatility of 4.6%: low 4.63$, high 5.08$
Factors to consider:
- Total employees count: 6 as of 2022
- Price in estimated range
- Earnings for 3 months up through Q1 are close to our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [3.84$, 8.14$]
- 2026-12-31 to 2027-12-31 estimated range: [3.96$, 8.34$]
Financial Metrics affecting the COYA estimates:
- Positive: with PPE of -4.4 at the end of fiscal year the price was neutral
- Negative: Operating cash flow per share per price, % of -11.66 <= 0.02
- Negative: negative Operating income
- Negative: negative Net income
- Positive: Shareholder equity ratio, % of 86.14 > 64.15
- Positive: -4.44 < Investing cash flow per share per price, % of -1.26
- Positive: Interest expense per share per price, % of 0 <= 0.01
- Negative: Inventory ratio change, % of 6.17 > 0.80
Short-term COYA quotes
Long-term COYA plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $6.00MM | $3.55MM | $7.95MM |
| Operating Expenses | $13.91MM | $20.80MM | $30.50MM |
| Operating Income | $-7.90MM | $-17.25MM | $-22.56MM |
| Non-Operating Income | $0.64MM | $1.65MM | $1.33MM |
| R&D Expense | $6.04MM | $11.89MM | $19.02MM |
| Income(Loss) | $-7.26MM | $-15.60MM | $-21.22MM |
| Taxes | $0.72MM | $-0.72MM | $0.00MM |
| Profit(Loss)* | $-7.99MM | $-14.88MM | $-21.23MM |
| Stockholders Equity | $35.64MM | $39.58MM | $43.03MM |
| Assets | $41.26MM | $44.35MM | $49.95MM |
| Operating Cash Flow | $-11.19MM | $-10.29MM | $-10.74MM |
| Investing Cash Flow | $-0.54MM | $-0.03MM | $-1.16MM |
| Financing Cash Flow | $38.43MM | $16.03MM | $20.39MM |
| Earnings Per Share** | $-0.79 | $-0.98 | $-1.27 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.